Journal article
Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders
Current opinion in pharmacology, Vol.8(1), pp.57-64
02/2008
DOI: 10.1016/j.coph.2007.12.002
PMCID: PMC2405764
PMID: 18206423
Abstract
Epigenetic chromatin remodeling and modifications of DNA represent central mechanisms for regulation of gene expression during brain development and in memory formation. Emerging evidence implicates epigenetic modifications in disorders of synaptic plasticity and cognition. This review focuses on recent findings that HDAC inhibitors can ameliorate deficits in synaptic plasticity, cognition and stress-related behaviors in a wide range of neurologic and psychiatric disorders including Huntington’s disease, Parkinson’s disease, anxiety and mood disorders, Rubinstein-Taybi syndrome and Rett syndrome. These agents may prove useful in the clinic for the treatment of the cognitive impairments that are central elements of many neurodevelopmental, neurological and psychiatric disorders.
Details
- Title: Subtitle
- Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders
- Creators
- Ted Abel - Department of Biology, University of Pennsylvania, 204G Lynch Laboratories, 433 South University Avenue, Philadelphia PA 19104-6018R. Suzanne Zukin - Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, 1300 Morris Park Ave, New York, NY 10461
- Resource Type
- Journal article
- Publication Details
- Current opinion in pharmacology, Vol.8(1), pp.57-64
- DOI
- 10.1016/j.coph.2007.12.002
- PMID
- 18206423
- PMCID
- PMC2405764
- NLM abbreviation
- Curr Opin Pharmacol
- ISSN
- 1471-4892
- eISSN
- 1471-4973
- Language
- English
- Date published
- 02/2008
- Academic Unit
- Molecular Physiology and Biophysics; Psychiatry; Psychological and Brain Sciences; Iowa Neuroscience Institute; Neuroscience and Pharmacology; Biochemistry and Molecular Biology
- Record Identifier
- 9984065829702771
Metrics
14 Record Views